TSO3 settles dispute with 3M Company

Stock symbol: TSX: TOS
Outstanding shares: 72,888,182 
QUEBEC CITY, July 2, 2013 /CNW Telbec/ - TSO(3) Inc. ("TSO(3)") an innovator 
in low-temperature sterilization technology for medical devices in healthcare 
settings, today announced that the Company has settled the ongoing dispute 
with the 3M Company ("3M") through the mediation process. 
On August 2, 2012, TSO(3) announced that the Company had terminated its 
Agreement with its former channel partner 3M, for the exclusive supply, 
distribution, license and service of the new STERIZONE(®) 125L+ Sterilizer 
branded as the 3M™ Optreoz™ 125-Z. The Agreement, dated December 2009 and 
amended in May 2011, provided conditions for either party to terminate the 
agreement. TSO(3) exercised this right and provided a letter of termination to 
3M on June 15, 2012. 3M had disputed TSO(3)'s right to terminate the agreement. 
In respect of the terms outlined in the settlement, limited details are being 
released. An amount of $2 million inclusive of the repurchase of inventory as 
well as settlement fees will be paid by TSO(3) to 3M. 
"We are satisfied with the terms of the settlement and that the dispute has 
been settled", stated R.M. (Ric) Rumble, CEO of TSO(3). 
Current Installed Base 
The current installed base of TSO(3) STERIZONE(®) 125L+ Sterilizers (3M™ 
Optreoz™ 125-Z) will be supported by TSO(3) until a new agreement is in 
place with a distribution partner. "We have maintained a close connection with 
the Canadian base of users and we have everything in place to maintain 
existing customers and provide additional support", concluded R.M. (Ric) 
About TSO(3) 
TSO(3), founded in Québec City in 1998, specializes in the research and 
development of innovative, high-performance medical instrument sterilization 
technology with high commercial potential. TSO(3) designs products for sterile 
processing areas in the hospital environment and offers an advantageous 
replacement solutions to other low temperature sterilization processes 
currently used in hospitals. For more information about TSO(3), visit the 
Company's Web site at www.tso3.com 
The statements in this release and oral statements made by representatives of 
TSO(3) relating to matters that are not historical facts (including, without 
limitation, those regarding the timing or outcome of any financing undertaken 
by TSO(3)) are forward-looking statements that involve certain risks, 
uncertainties and hypotheses, including, but not limited to, general business 
and economic conditions, the condition of the financial markets, the ability 
of TSO(3) to obtain financing on favourable terms and other risks and 
The TSX has neither approved nor disapproved the information contained herein 
and accepts no responsibility for it. 
Caroline Côté Vice President - Investor and Business Relations 
418651-0003, Ext. 237ccote@tso3.com 
To view this news release in HTML formatting, please use the following URL: 
CO: TSO3 Inc.
ST: Quebec
-0- Jul/02/2013 10:30 GMT
Press spacebar to pause and continue. Press esc to stop.